GLSYNTHESIS, INC.

Biotech · Private

Fluorosome-trans-abcg2 assay reagent for high-throughput characterization of drug interactions with ABCG2 transporter

Grants
$2.6M
4 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
4
0 granted · 4 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Production and inhibition assay for bile salt export protein$243,266
Federal grantDepartment of Health and Human Services · Phase I · A novel drug detection assay using fluorescent biosensor technology$320,466
Federal grantDepartment of Health and Human Services · Phase II · Novel Antithrombotic Diadenosine Tetraphosphate Analogs$1,417,233
Federal grantDepartment of Health and Human Services · Phase II · Development of a fluorescence ABCG2 liposomal multidrug transporter assay$597,909
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2429Advanced Vision Technologies, Inc.——
2430STELLULAR BIO, INC.——
2431SYNTHETIC VECTOR DESIGNS, LLC——
2432GLSYNTHESIS, INC.——
2433PRAXIS BIORESEARCH, LLC——
2434Coactigon, Inc.——
2435SPIRIFY PHARMA INC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 4
  • Selective Antibacterials For Clostridium Difficile Infectionsapplication
  • Novel Antithrombotic Diadenosine Tetraphosphates And Related Analogsapplication
  • Reactive Pyrophosphoric And Bisphosphonic Acid Derivatives And Methods Of Their Useapplication
  • Purine And Isosteric Antibacterial Compoundsapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.